For the treatment of cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma, HDAC inhibitors (HDACi) have been approved [46, 47]. The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.